Following the US Food & Drug Administration approval of Dr. Reddy’s ANDA for Lamotrigine XR tablets, the company has launched Lamotrigine Extended-Release tablets. The Lamotrigine XR tablets are
The open label, single-arm, multicenter trial will enroll 80 patients in the US, Canada and Europe to evaluate enzalutamide as a single agent against AR-positive, TNBC. All patients
As part of the agreement, DHK plans to offer Arrayit genomic testing services by extending national network of 800 American Medical Center (AMC) facilities and include medical doctors,
Suitable for pharmacists, the new development can be used in laboratories and early clinical trials, while the filling parameters of the series can be easily scaled-up to production
The supplement is designed to protect against axon degeneration damage or trauma persistent during the contact sports. Niagen is the brand of nicotinamide riboside that is believed to
Completely integrated with BioClinica’s product suite and 21 CFR Part 11 compliant, the new platform offers one easy tool to access multiple eClinical applications, as well as analyze
The formulation received Japan manufacturing and marketing authorization on 15 February 2013, and has been placed on the country’s National Health Insurance (NHI) drug price list on 21
The license allows the company to manufacture the humanized, monoclonal antibody under recombinant conditions in a mammalian cell line (CHO cells) in its GMP facility in Teterow, Germany.
Designed to assess ascending doses of AHRO-001 in healthy adult volunteers, the randomized, double-blind study is being conducted in Russia with AtheroNova’s licensing partner, OOO CardioNova. The safety,
The patent expires in 2028 and covers methods of inhibiting inflammation by means of intravenous immunoglobulin (IVIG)-derived, sialylated Fc regions. Momenta president and chief executive officer Craig Wheeler
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.